Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Duearity has entered into an agreement with a national distributor in the USA

Duearity

Duearity Americas Inc has entered into a distributor agreement with a national distributor in the US. The distributor, Westone Laboratories, with the help of its network among clinics in the country, has tested Tinearity G1 with positive results. Westone covers the majority of essential channels on the US market.

Westone has evaluated Tinearity G1 and has included the product in the company's product portfolio as they make the assessment that the conditions for selling Tinearity G1 in the US are good. Westone Laboratories covers multiple channels throughout the United States, including audiologists, general practitioners, hearing aid specialists, hearing dispensers and Veteran Affairs clinics. Westone sells only hearing products and has been in business for more than 60 years. Their network among clinics is extensive and the company's reputation is very good. Westone has its own salespeople and agents throughout the United States.

- Westone is a perfect partner for Duearity as they have an extensive network and very long experience. Not least, they have an extremely good reputation in the USA. Westone sells products in all states and the fact that they cover five out of six essential channels means that Duearity has thus laid the foundation for sales in larger volumes in the USA, says Fredrik Westman, CEO of Duearity AB.

Duearity Americas Inc is in discussions with more distributors in the US. Duearity and the actor who entered into an agreement of intent with Duearity, which was announced on November 3, 2023, has chosen not to continue the negotiations on a distributor agreement. On February 6, 2024, Duearity announced that an agreement had been entered into with Oaktree Products. Westone and Oaktree have a well-developed collaboration and complement each other well.

Westone Laboratories, Based in Colorado Springs, CO, has been a leader in hearing health for over 60 years providing quality custom-fit earpieces, hearing protection and audiology supply products. Westone’s expertise extends beyond the healthcare industry and includes world-class communications earpieces for pilots; with each branch of the US Armed Forces using Westone’s products.

For more information, please contact


Fredrik Westman, CEO
+46 738 - 145 215
fredrik.westman@duearity.com 
www.duearity.com

About Duearity AB (publ)


Duearity is a medtech company that develops and produces solutions aiming to treat and relieve tinnitus symptoms and make everyday life easier for those who suffer from tinnitus. The company will offer the products Tinearity and Tinearity-AI.

Tinearity G1 is CE marked, has 510(k) clearance and is sold in the EU, in the US, Australia and New Zealand.

Tinearity transmits white noise using non-invasive Bone Conduction Technology to the inner ear in order to treat and relieve symptoms. Tinearity AI will help people anticipate the symptoms and relieve their discomfort.

The company is listed on Nasdaq First North. The company's headquarters are located in Malmö, Sweden.
Certified Adviser is Svensk Kapitalmarknadsgranskning AB (SKMG), www.skmg.se.
www.duearity.com.

Attachments


Duearity has entered into an agreement with a national distributor in the USA

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.